Long-acting insulin therapy, whose effects are studied in a newly developed and controlled study group, has been shown to reduce the risk of severe hypoglycaemia (hypoglycaemia) in patients with type 2 diabetes.
Scientific studies of long-acting insulin therapy, which examined effects in a newly developed and controlled study group, have shown that new long-acting insulin therapy reduces type 2 diabetes patients' risk of serious blood-sugar lowering in patients.
At this year's annual meeting of the American Diabetes Association, the 77th edition of the US San Diego city, the results of studies on new generation insulins were presented.
In a study published simultaneously in the New England Journal of Medicine, it has been reported that long-acting insulin, currently in use with the new generation long-acting insulin, does not produce sufficient insulin to function properly or when the body's cells do not respond to insulin, The risk of developing vascular disease was also compared in terms of risk.
In a study involving a total of 7,637 participants from different countries and two years of controlled study groups, the risk of cardiovascular death, heart attack and stroke were similar in both groups, whereas the risk of newborn insulin as significantly lower than the current insulin And a 43 percent reduction in the risk of severe hypoglycaemia with adverse side effects.